CURRENT
ISSUE
1563

Antiviral drugs can be used for treatment and prophylaxis of seasonal influenza (see Table 1). Frequently updated information on influenza activity, influenza testing, and antiviral resistance is available from the CDC at www.cdc.gov/flu.

ANTIVIRAL DRUGS — The neuraminidase inhibitors oseltamivir (Tamiflu, and generics), which is taken orally, and zanamivir (Relenza), which is inhaled, are FDA-approved for prophylaxis and treatment of acute uncomplicated influenza. The IV neuraminidase inhibitor peramivir...  Continue reading

More from Issue 1563
Previous Issue: 1562      December 17, 2018
Coming Soon
A New Epinephrine Syringe (Symjepi) for Anaphylaxis
Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation
Qbrexza - A Glycopyrronium Cloth for Axillary Hyperhidrosis
Revefenacin (Yupelri): A Once-Daily Treatment for COPD
OTC Primatene Mist Returns
Lipid-Lowering Drugs
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1563

Tildrakizumab-asmn (Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.1

STANDARD TREATMENT — Topical corticosteroids are generally recommended for initial treatment of mild to moderate plaque psoriasis. The topical retinoid tazarotene (Tazorac, and others) and topical vitamin D analogs such as calcipotriene (Dovonex, and others) can also be used, alone or in combination with topical corticosteroids. For patients with moderate to severe disease, systemic ... Continue reading